Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

UnitedHealth Group (UNH 1.05%) and Eli Lilly (LLY +1.45%) are two of the largest and most powerful healthcare companies in ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...